Drugs / CD19+CD22 CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02443831 | Apr 2016 → Dec 2026 expected | acute lymphoblastic leukemia | University College, London | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19+CD22 CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02443831 ↗ |
| Modality | Cell therapy | “This is a multi-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product named CD19+CD22 Chimeric Antigen Receptor...” NCT02443831 ↗ |
| Route | Intravenous | “given as an intravenous injection” NCT02443831 ↗ |